Clinical Policy: Cholic Acid (Cholbam)
Reference Number: CP.PHAR.390
Effective Date: 12.01.18
Last Review Date: 11.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Cholic acid (Cholbam®) is a bile acid.

FDA Approved Indication(s)
Cholbam is indicated for:
- Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs)
- Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption

Limitation(s) of use: The safety and effectiveness of Cholbam on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Cholbam is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Bile Acid Synthesis Disorders or Peroxisomal Disorders (must meet all):
      1. Diagnosis of one of the following (a or b):
         a. Bile acid synthesis disorders due to SEDs;
         b. PDs, including Zellweger spectrum disorders;
      2. Diagnosis is confirmed by at least one of the following (a or b):
         a. An abnormal urinary bile acid consistent with a bile acid synthesis or Zellweger spectrum disorder as confirmed by Fast Atom Bombardment ionization – Mass Spectrometry (FAB-MS) analysis;
         b. Molecular genetic testing consistent with diagnosis (e.g., biallelic pathogenic variants in ABCD3, AKR1D1, AMACR, HSD3B7, CYP27A1, CYP7B, or PEX genes);
      3. Prescribed by or in consultation with a hepatologist, gastroenterologist, or metabolic disease specialist;
      4. Documentation of current (within the last 30 days) liver function test results;
      5. Dose does not exceed 17 mg/kg per day.
Approval duration: 3 months

B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Bile Acid Synthesis Disorders or Peroxisomal Disorders (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy as evidenced by improvement in liver function tests with both of the following (a and b):
      a. Alanine transaminase (ALT) or aspartate transaminase (AST) values reduced to less than 50 U/L or baseline levels reduced by 80%;
      b. Total bilirubin values reduced to less than or equal to 1 mg/dL;
   3. If request is for a dose increase, new dose does not exceed 17 mg/kg/day.

Approval duration:
Medicaid/HIM – 12 months
Commercial – Length of Benefit

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
      Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   FDA: Food and Drug Administration
   PDs: peroxisomal disorders
   SEDs: single enzyme defects

   Appendix B: Therapeutic Alternatives
   Not applicable
Appendix C: Contraindications/Boxed Warnings
None reported

Appendix D: General Information
- Bile acid synthesis disorders and peroxismal disorders may be diagnosed with either genetic testing or urine bile acid profile by fast atom bombardment-mass spectrometry. Bile acid testing by fast atom bombardment-mass spectrometry assesses the phenotypic, biochemical response to a genetic disorder.
- Treatment should be initiated and monitored by a hepatologist, gastroenterologist, or metabolic disease specialist.
- Discontinue Cholbam if liver function does not improve within 3 months of starting treatment or complete biliary obstruction develops.
- Discontinue treatment with Cholbam at any time if there are persistent clinical or laboratory indicators of worsening liver function or cholestasis.
- The safety and effectiveness of Cholbam on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bile acid synthesis disorders due to SED, PD including Zellweger spectrum disorders</td>
<td>10 to 15 mg/kg/day administered PO in one or two divided doses</td>
<td>17 mg/kg/day</td>
</tr>
<tr>
<td>For concomitant familial hypertriglyceridemia: 11 to 17 mg/kg/day PO in one or two divided doses</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

VI. Product Availability
Capsules: 50 mg, 250 mg

VII. References

Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created: adapted from previously approved policy CP.CPA.243; added specialist requirement; no significant change from previously approved corporate policy; references reviewed and updated.</td>
<td>08.14.18</td>
<td>11.18</td>
</tr>
<tr>
<td>4Q 2019 annual review: no significant changes; references reviewed and updated.</td>
<td>07.30.19</td>
<td>11.19</td>
</tr>
<tr>
<td>4Q 2020 annual review: updated criteria to require diagnosis confirmation, allow metabolic disease specialist, and require evidence of improvement in LFTs for continued therapy; shortened</td>
<td>06.26.20</td>
<td>11.20</td>
</tr>
</tbody>
</table>
**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.
Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.